Abemaciclib plus endocrine therapy in high-risk, node-positive early breast cancer in Italian practice: interim analysis of prospective observational IT-PATH study
Background Abemaciclib plus endocrine therapy (ET) is an established adjuvant treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC), based on monarchE trial. Prospective real-world data on persistence, adherence, dose m...